Scisparc Ltd. (SPRC) Stock Performance

  • Price movement: Shares fell 10.45 % during the 24‑hour period ending 11:41 PM CET on Friday, 23 Nov 2026.
  • Current price: USD 1.09 on major exchanges.
  • Shares outstanding: 573.2 k.
  • Market capitalization: USD 778.5 k.
  • Volume (last 24 h): USD 530.3 k.
  • Monthly change: -76.05 % since the end of the previous month.
  • 200‑day moving average: USD 5.94.
  • 52‑week high: USD 35.47 (27 Oct 2025).
  • 52‑week low: USD 1.18 (22 Oct 2026).

Recent Corporate Announcement

SciSparc Ltd. announced that its subsidiary, NeuroThera Labs Inc., has advanced a U.S. FDA‑approved Phase IIb clinical trial for Tourette syndrome. Key points include:

  1. Product: SCI‑110, a cannabinoid‑based oral formulation containing dronabinol and palmitoylethanolamide.
  2. Manufacturing: Completion of manufacturing and batch‑release certification from a European Qualified Person.
  3. Logistics: Shipment of trial material to study sites in the United States, Germany, and Israel.
  4. Trial status: Site‑initiation activities completed; patient enrollment is expected to begin shortly.
  5. Objectives: Evaluation of efficacy, safety, and tolerability in adults with Tourette syndrome.
  6. Strategic implication: Represents progress toward the next phase of SciSparc’s cannabinoid‑derived therapeutic portfolio.

TickerTrade %Current PriceMarket CapNotes
SADE.TA (Sade Real Estate‑ys)0 %ILA 758.4ILA 69.7 mnNo change
HUBC (Hub Cyber Security)-7.98 %USD 0.15USD 538.8 kForm 3 filed; single shareholding by director Richard Poalone
MWE.L (Mti Wireless Edge)+3.2 %GBX 64GBX 74.1 mnP/E ratio 13.84
SCNI (Scinai Immunotherapeutics Ltd.)+0.16 %USD 0.56USD 826.7 k—
SLXN (Silexion Therapeutics)+7.14 %USD 0.19USD 917.4 k—

Company Profile

SciSparc Ltd. is headquartered in Tel Aviv, Israel, and focuses on developing cannabinoid technologies for central nervous system disorders. The company operates globally and serves a worldwide customer base.